NHL33 : An Australasian Leukaemia & Lymphoma Group (ALLG) Window study of Acalbrutinib plus Rituximab (Mabthera) followed by Cytarabine, Oxalipatin, Dexamethasone & Rituximab ( R-DHAOx) + Autologous Stem cell Transplant (ASCT) in fit Mantle Cell Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18-65Age 18-65

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMantle Cell Lymphoma

Trial Overview Read MoreRead more

This phase II trial is assessing the safety and effectiveness of using targeted therapy and chemotherapy to treat fit patients with previously untreated mantle cell lymphoma, with or without a stem cell transplant and further maintenance therapy.
 

This trial is treating patients with mantle cell lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An Australasian Leukaemia & Lymphoma Group (ALLG) Window study of Acalbrutinib plus Rituximab (Mabthera) followed by Cytarabine, Oxalipatin, Dexamethasone & Rituximab ( R-DHAOx) + Autologous Stem cell Transplant (ASCT) in fit Mantle Cell Lymphoma

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Commercial Sponsor

Acerta Pharma BV

Summary

All eligible patients will receive Rituximab and Acalabrutinib, followed by 4 cycles of R-DHAOx chemotherapy at trial commencement. Patients who demonstrate at least a partial response to R-DHAOx, will go on to receive BEAM Autologous stem cell transplant in the consolidation phase of the trial, followed by maintenance therapy with Acalabrutinib and Rituximab. Patients who show less than partial response to R-DHAOx will be taken off study and treated as per the local treatment guidelines. The response will be determined by review of a PET/CT scan taken after the patient has completed 4 cycles of R-DHAOx.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next